Pasar al contenido principal

SINTESIS DE COMPUESTOS BIOLOGICAMENTE ACTIVOS. DESARROLLO DE NUEVAS METODOLOGIAS SINTETICAS, ANALOGOS DE HORMONAS Y LIBERACION DIRIGIDA DE FARMACOS

CTQ2014-56361-P

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Half-sandwich complexes of Ir(III), Rh(III) and Ru(II) with the MaxPhos ligand: metal centred chirality and cyclometallation

  • Téllez, Juan
  • Gallen, Albert
  • Ferrer, Joaquina
  • Lahoz, Fernando J.
  • García-Orduña, Pilar
  • Riera, Antoni
  • Verdaguer, Xavier
  • Carmona, Daniel
  • Grabulosa, Arnald
The reaction of the acetylacetonates [(η5-C5Me5)M(acac)Cl] with (SP)-[HMaxPhos][BF4] afforded cationic complexes with the formula (SM,RP)-[(η5-C5Me5)MCl(MaxPhos)][BF4] (M = Rh (1), Ir (2)). The reaction of (SP)-MaxPhos with [RuCl(μ-Cl)(η6-p-MeC6H4iPr)]2 and NH4X afforded (SRu,RP)-[(η6-p-MeC6H4iPr)RuCl(MaxPhos)][X] (X = BF4 (3), PF6 (3')). The complexes have been completely characterized by analytical and spectroscopic means, including the determination of the crystal structures of 1, 2 and 3'. Treatment of the iridium complex 2 with AgBF4, at 253 K, resulted in the intramolecular cyclometallation of one of the tert-butyl substituents of the MaxPhos diphosphane ligand, affording a mixture of isomers of (SIr,RP1,SP2 and RIr,RP1,RP2)-[(η5-C5Me5)Ir(MaxPhos)][BF4] (4a and 4b). However, rhodium complex 1 and ruthenium complex 3 reacted with AgBF4 forming the expected unsaturated intermediates "(ηn-ring)M(MaxPhos)" which were trapped by MeCN, affording the cationic adducts (SM,RP)-[(ηn-ring)M(MaxPhos)(MeCN)][BF4]2 (M = Rh (5), Ru (6)). Only one epimer at the metal was isolated in high yield for the complexes 1, 2, 3, 3', 5 and 6 and the metallation of 2 to give 4 occurs with high diastereoselectivity., We thank the Ministerio de Economía y Competitividad (MINECO) of Spain (CTQ2015-67366-P, CTQ2015-65040-P and CTQ2014-56361-P), IRB Barcelona, Gobierno de Aragón and European Social Fund (Grupo Consolidado: Catalizadores Organometálicos Enantioselectivos) for financial support. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease

  • Rol, Alvaro
  • Todorovski, Toni
  • Martin-Malpartida, Pau
  • Escolà, Anna
  • González-Rey, Elena
  • Aragón, Eric
  • Verdaguer, Xavier
  • Vallès-Miret, Mariona
  • Farrera-Sinfreu, Josep
  • Puig, Eduard
  • Fernández-Carneado, Jimena
  • Ponsati, Berta
  • Delgado, M.
  • Riera, Antoni
  • Macías, M. J.
Ulcerative colitis and Crohn’s disease are forms of inflammatory bowel disease whose incidence and prevalence are increasing worldwide. These diseases lead to chronic inflammation of the gastrointestinal tract as a result of an abnormal response of the immune system. Recent studies positioned Cortistatin, which shows low stability in plasma, as a candidate for IBD treatment. Here, using NMR structural information, we design five Cortistatin analogues adopting selected native Cortistatin conformations in solution. One of them, A5, preserves the anti-inflammatory and immunomodulatory activities of Cortistatin in vitro and in mouse models of the disease. Additionally, A5 displays an increased half-life in serum and a unique receptor binding profile, thereby overcoming the limitations of the native Cortistatin as a therapeutic agent. This study provides an efficient approach to the rational design of Cortistatin analogues and opens up new possibilities for the treatment of patients that fail to respond to other therapies., A.Rol was a recipient of a PhD fellowship from the Generalitat de Catalunya (FI) and A.E. and E.P. were recipients of PhD fellowships granted by the Severo Ochoa Program(FPI). T.T. was a postdoctoral fellow co-funded by the Marie Skłodowska-CurieCOFUND actions (IRB Barcelona Interdisciplinary Postdoc Programme). This work wassupported by the following grants: CTQ2014-56361-P and CTQ2017-87840-P (A.Riera)and RTI2018-100700-B-100 (M.D.) from the Spanish Ministry of Economy, Industryand Competitiveness (MINECO); and by AGAUR (SGR-50). We also acknowledge institutional funding from MINECO through the Centers of Excellence Severo OchoaAward given to IRB Barcelona, as well as from the CERCA Program of the Generalitat deCatalunya. M.J.M. is an ICREA Programme Investigator.